Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

As Biosimilar Meeting Requests Rise, So Do FDA's Performance Goal Challenges

Executive Summary

Growing number of products participating in BsUFA program, coupled with budgetary challenges, have made FDA attainment of some early goals under the Biosimilar User Fee Act difficult.

Advertisement

Related Content

FDA Proposes Dedicated Biosimilar 'Unit' For BsUFA II
FDA Met Biosimilar Review Timelines But Missed Meeting Goals In 2015
Biosimilar Market Formation Isn't Going According To Plan
Biosimilar User Fee Negotiations Won't Start Until 2016
Zarxio Clinical Development Timeline
Biosimilar Pathway Quickly Becoming Crowded In U.S.
Biosimilars Program Will Be “Under-Resourced” In Early Years As Industry Grows

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS057081

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel